- The surge in bulk commodities hides risks, AI’s aura fades—how long can this commodity bull market last?
- The yen retraces half of its intervention-driven gains on the weekly chart as the crucial 160 level approaches; a September rate hike may be the last line of defense.
- Humana Assistans wins Swedish appeals court leave to challenge state damages ruling
- Clene Q2 FY26 net loss widens 81% to $13.42 million
- Standard Nuclear director Seth Michael Cohen files initial beneficial ownership statement
- 1847 Holdings Q2 FY26 net loss widens to $5.95 million; revenue falls 12.53% to $1.57 million
- Jæren Sparebank sets new bond interest rate at 5.13%
- Nuvera Q2 FY26 net loss narrows 62.09% to 160,770; revenue slips 0.8% to 17.66 million
- Quantum Cyber Q2 FY26 net loss widens to $11.02 million; operating loss widens to $9.89 million
- Eidesvik Offshore to present Q2 2026 results in digital briefing
- CCSC Technology International announces special meeting of Class A shareholders
- Genvor FY26 Q3 net loss widens 542.7% to $2.56 million
- Aptera Motors appoints Wellington J. Reiter as independent director, Audit Committee member
- PDS Biotech holds annual shareholder meeting, quorum reached
- Annovis Bio Q2 FY26 net loss widens to $14.82 million; R&D expenses more than doubled to $12.01 million
- GT Biopharma Q2 FY26 net loss narrows to $4.5 million; operating loss widens to $4.5 million
- Canary Gold reports visible gold grains in 29 of 30 RC samples at Madeira River project in Brazil
- SK Hynix’s performance surges in the first half of the year, with employee compensation and R&D investment soaring simultaneously
- Replimune Group 1Q Loss $69.8M >REPL
- PMV Pharmaceuticals 2Q Loss/Shr 34c >PMVP
- PMV Pharmaceuticals 2Q Loss $18.1M >PMVP
- Replimune Group 1Q Loss/Shr 72c >REPL
- Galectin Therapeutics 2Q Loss/Shr 14c >GALT
- Conifex Timber 2Q Rev $23M >CFF.T
- Montega raises Fabasoft price target to EUR 27, reiterates buy rating
- FGI INDUSTRIES LTD <FGI.O>: BENCHMARK RAISES TARGET PRICE TO $13 FROM $8
- First Carolina FY26 Q2 net income rises 10.87% to $5.1 million
- Amundi Physical Metals issues 9,000 Amundi Physical Gold ETC securities in Tranche 897
- RedotPay delays US IPO plans amid regulatory hurdles
- JinkoSolar schedules Q2 results release, earnings call
- TIDEWATER RENEWABLES LTD <LCFS.TO>: RBC RAISES TO OUTPERFORM FROM SECTOR PERFORM; RAISES TARGET PRICE TO C$25 FROM C$12.5
- LanzaTech Q2 FY26 net income swings to profit of $184.3 million; revenue slips 1% to $9 million
- Galectin Therapeutics Q2 FY26 net loss widens 21.17% to $9.11 million
- HANSAINVEST lifts q.beyond stake to 3.44% voting rights
- Prosafe updates financial calendar ahead of Q2, first-half 2026 results webcast
- Swiss Franc edges up from lows against the US Dollar with US Retail Sales on tap
- Regulatory filings disclosed on Friday show that in the first half of 2026, Samsung Electronics’ R&D investment hit a record high of 27.3 trillion won (equivalent to $19 billion). The Korean tech giant’s R&D expenditure for January to June rose 51.5% year-on-year from 18.06 trillion won, setting a new half-year historical record. Samsung Electronics also set a new half-year record for equipment investment in the first half of the year, reaching 28 trillion won, an increase of nearly 5 trillion
- BIRD CONSTRUCTION INC. <BDT.TO>: ATB CORMARK CAPITAL MARKETS RAISES TARGET PRICE TO C$87 FROM C$57
- Tenet Fintech signs 3-year GoldRiver services deal with CAD 225 million annual minimum guarantee
- Foreign media: SOL consolidation with decreasing volume is approaching a decisive move
- Correct: LanzaTech Global Sees 2026 Adjusted Ebitda Negative $22M-$26M >LNZA
- Tres Tentos publishes 2Q26 results presentation
- Mako Mining posts Q2 2026 profit rise on higher realized gold prices, more ounces sold
- Helus Pharma cites currency switch, share consolidation and Nasdaq move as key Q1 FY2027 factors for Cybin
- KINDERCARE LEARNING COMPANIES INC <KLC.N>: JP MORGAN CUTS TO UNDERWEIGHT FROM NEUTRAL
- LanzaTech Global 2026 Adjusted Ebitda Negative $22M-$26M >LNZA
- TuHURA Biosciences: Expect to Initiate Phase 1b/2 Trial of VISTA in mutNPM1 R/r AML in 2H 2026 >HURA
- LanzaTech Global Sees 2026 Rev $50M-$55M >LNZA
- TuHURA Biosciences: Expect to Receive Orphan Drug Designation in MCC in 2H 2026 >HURA
- LanzaTech Global Sees 3Q Rev $8M-$11M >LNZA
- TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA
- NexPoint Diversified Real Estate Trust returns to profit in Q2 FY26; revenue falls 8.07% to $19.34 million
- PLDT says SGV keeps 2025 audit opinion as company plans amended 2025 Form 20-F filing
- "Ocado, the 'Tesla of Groceries', sees a dramatic 45% rebound in stock price! New warehouse in South Korea ignites valuation recovery; Ocado enters a critical inflection point for 'distress reversal'"
- V Ten Metals starts inaugural RC drill program at Tanami nickel-copper-PGE project in Australia
- LanzaTech Global 2Q Adjusted Ebitda Negative $7.6M >LNZA
- LanzaTech Global 2Q Net Boosted by Non-Cash Unrealized Gain on Investment in SGLT >LNZA
- TuHURA Biosciences: Cash and Cash Equivalents of $1M at June 30 >HURA
- BRIEF-SurgePays Q2 EPS USD 0.05
- SurgePays returns to profit in Q2 FY26; revenue rises 40.7% to $16.2 million year over year
- Raizen reclassifies Argentina fuel distribution unit as discontinued operation
- Gri Bio Q2 FY26 net loss narrows to $1.64 million; R&D expenses drop 78.34% to $407,000
- Cybin net loss widens to $47.8 million in FY27 Q1
- SurgePays 2Q Rev $16.2M >SURG
- LanzaTech Global 2Q Net $184.3M >LNZA
- Cybin renames key subsidiaries under Helus reorganization plan
- mDR NTA per share stands at S$ 0.09 as of Aug. 13, 2026
- South African Rand: ZAR outperforms on carry and Gold – Societe Generale
- Spot gold has just surpassed the $4,360.00/oz mark, now quoted at $4,360.34/oz, up 0.22% for the day; COMEX gold futures main contract is now quoted at $4,416.80/oz, down 0.08% for the day.
- Matador Resources Chairman, CEO Joseph Foran acquires $778,800 of common shares
- Bank of England to Test Interoperability Between Stablecoins and the Digital Pound
- Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3
- Borr Drilling director Jeffrey Currie buys 125,000 common shares for $501,638
- Braskem 2Q26 net income turns to profit at US$664 million; recurring EBITDA rises to US$1.04 billion
- Cable One Names Heather McCallion Chief Operating Officer
- Vital Infrastructure Property Trust declares $0.03 per unit August distribution
- XAU Resources says TSXV review advances on proposed Quartzstone deal with QS Holdings
- 992.5 Million XRP Now Locked, But Ripple Is Not Behind It
- Shytoshi Kusama's Litecoin Connection? SHIB Veteran Gives Take
- Lantern Pharma 2Q Research and Development Expenses About $1.8M >LTRN
- Lantern Pharma 2Q Loss/Shr 57c >LTRN
- IQSTEL Sees 6-Mos Rev $207M >IQST
- Beneficient 1Q Rev $12.2M >BENF
- Beneficient 1Q Loss/Shr 47c >BENF
- Milestone Scientific 2Q Loss $1.06M >MLSS
- Edible Garden AG 2Q Loss/Shr $18.79 >EDBL
- Edible Garden Q2 FY26 net loss narrows to $3.3 million; revenue rises 12.8% to $3.6 million
- U.S. Physical Therapy names Nchacha Etta CFO effective Sept. 1, 2026
- BTQ Technologies schedules shareholder webinar on Q2 results, corporate update
- Beneficient FY27 Q1 operating loss narrows 99.4% to $377,000; revenue turns positive to $12.17 million
- MCX launches crude sunflower oil futures contract
- Applied Materials CFO Hill speaks at Citi Global TMT investor conference fireside chat
- Base Carbon Q2 FY26 loss per share widens to $0.02; total assets fall to $103.44 million
- Lantern Pharma Q2 FY26 operating loss narrows 25% to $3.5 million; net loss widens to $7.1 million
- Canopy Growth says Kincardine facility wins renewed EU GMP certification
- Cuentas CEO Shalom Arik Maimon buys USD 2,872 of common shares
- BridgeBio prices secondary offering of 5 million shares by KKR Genetic Disorder LP
- A Weak Rupee Does Not Automatically Mean Bitcoin Will Rise in India
- IQSTEL to host Q2 2026 earnings call
- Müller-Die lila Logistik H1 FY26 net profit drops 32.3% to EUR 852,000; revenue rises 1.1% to EUR 124.12 million
